Hydrocolloid patch for cold sores with antiviral and uv-protective properties
A novel hydrocolloid patch for cold sores, featuring zinc oxide and a proprietary antiviral agent, offers antiviral and UV protection. It maintains a moist wound environment, prevents irritation, and matches natural lip tones for discreet use, addressing both physical symptoms and social stigma.
Overview
The hydrocolloid patch is an innovative solution for managing herpes-related cold sores. It integrates zinc oxide, known for its antiviral and UV-protective properties, with a proprietary FDA-approved antiviral ingredient. This combination not only accelerates healing but also serves as a preventive measure against viral spread and UV exposure. The patch maintains a moist wound environment, reduces irritation, and its skin-tone matching design enhances user confidence, addressing both the physical symptoms and social stigma associated with cold sores.
Technical specifications
- Active ingredients: Zinc oxide and a confidential FDA-approved antiviral agent
- Benefits: Moist wound environment, antiviral and UV protection, prevents viral spread and irritation
- Design: Color-matched to natural lip tones for discretion
- Assessment methods: Image-based healing assessment and mental health surveys
- Development plan: Phased approach with prototype refinement, stability testing, and clinical evaluation
Technology readiness level
Currently at TRL 2, the patch is in the early stages of technology development. A phased validation plan over 18–24 months includes prototype refinement, stability testing, and clinical evaluations to progress towards commercialization.
About Columbia University
Columbia University is a comprehensive private research university in New York City, combining an Ivy League academic profile with globally engaged scholarship and professional education. Its integration with a major hospital system through Columbia University Irving Medical Center and NewYork-Presbyterian enables clinical collaboration, access to diverse patient populations, and regulated studies at scale. State-of-the-art laboratories and shared core facilities across the Morningside and Manhattanville campuses support co-located industry projects, while proximity to New York’s finance, media, and healthcare ecosystems streamlines talent pipelines and pilot deployments. Industry engages via sponsored research, affiliate programs, executive education, and convenings that connect faculty expertise with corporate R&D priorities. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD, alongside New York State and philanthropic sources. Columbia Technology Ventures provides IP management, licensing, startup support, and translational funding mechanisms that lower barriers to commercialization.
Inquire about this partnering listing
Industry applications
delivered to your inbox.